Analyzing breast cancer responses to chemotherapy in real time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project focuses on identifying candidates for drug resistance in breast cancer patients undergoing neo-adjuvant chemotherapy (NAC). It employs a combination of molecular analyses of biopsies taken before and after NAC, in vitro patient-derived organoids that mimic individual responses to treatment, and the isolation of circulating tumor cells at various stages of NAC. The goal is to better understand the molecular mechanisms behind chemotherapy resistance and improve treatment outcomes for aggressive breast cancer types.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Woman over 18
2. Signed consent to participate
3. Invasive mammary adenocarcinoma proven histologically and / or cytologically
4. Indication of CNA retention by the referring clinical team.
5. No contraindication to CNA.
6. Selected indication of the post-CNA surgery sequence, then radiotherapy
7. Performance index ≤ 1 (WHO).
8. Affiliation to a social security scheme, or beneficiary of such a scheme

Exclusion Criteria:

1. Planned therapeutic sequence: CNA, followed by neoadjuvant radiotherapy (HIST-RIC clinical trial for example) before surgery
2. Metastatic disease at diagnosis
3. Patient relapsed from breast cancer precede
4. Other malignant disease in the previous 3 years, with the exception of cervical carcinoma in situ or skin basal cell carcinoma and any other cancerous pathology considered to have been properly treated and at low risk of relapse.
5. Woman pregnant or likely to be (without effective contraception) or breastfeeding
6. Person in an emergency situation, adult person subject to a legal protection measure (adult under guardianship, guardianship or legal protection), or unable to express consent.
7. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons

Where it's running

• Institut Paoli-Calmettes
  Marseille, Marseille, France Recruiting

Study contacts

• Principal investigator: François BERTUCCI, Pr — Institut Paoli-Calmettes
• Study coordinator: j PAKRADOUNI, PharmD,PhD
• Email: drci.up@ipc.unicancer.fr
• Phone: 0491223778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Negative pressure wound therapy after mastectomy

  This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.

  Recruiting Dalarna County Council, Sweden · Falun · NCT07607366

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care

  This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas and 1 other locations · NCT07242118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.